Principal Therapy Area: Cancer
£195 / $340 / €245
OncoVAX is a patient-specific active immunotherapy. OncoVAX is an autologous vaccine therapy, made from irradiated tumour cells obtained from the patient after surgery. It works by stimulating the patient’s own immune system to destroy cancer cells remaining after surgery; unlike typical vaccines it does not stimulate a general immune response, but is designed to specifically affect only an individual’s cancer cells. The vaccine is administered by four intradermal injections.
OncoVAX has positive statistically-significant Phase IIIa results showing 25 per cent improvement in overall survival.
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org